Back to top
more

Universal Health Services (UHS)

(Delayed Data from NYSE)

$205.26 USD

205.26
632,500

+0.95 (0.46%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $205.49 +0.23 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 11% (28 out of 250)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Invest in Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.

DexCom (DXCM) Launches One+ Real-time CGM System in Europe

by Zacks Equity Research

DexCom (DXCM) unveils its new CGM system, Dexcom ONE+, which is set to provide easy and effective care to diabetic patients.

McKesson (MCK) Beats on Q3 Earnings, Raises FY24 EPS View

by Zacks Equity Research

McKesson's (MCK) third-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.

Microbot Medical (MBOT) Files IDE to Start Human Clinical Study

by Zacks Equity Research

Microbot Medical (MBOT) files an IDE with the FDA, approval of which will enable the company to proceed with its human clinical study in the United States.

Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings

by Zacks Equity Research

Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.

Hologic (HOLX) Introduces Genius Digital Diagnostics System

by Zacks Equity Research

Hologic's (HOLX) Genius Digital Diagnostics System will assist laboratories and healthcare providers with the information needed to make more timely and successful treatment decisions for patients.

Philips (PHG) Receives FDA Class 1 Recall for BrightView SPECT

by Zacks Equity Research

Philips (PHG) receives an FDA Class 1 recall for BrightView imaging systems.

PacBio's (PACB) New Kits to Boost Its Revio Sequencing System

by Zacks Equity Research

PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.

InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS

by Zacks Equity Research

InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.

CONMED (CNMD) Misses on Q4 Earnings, Beats Revenue Estimates

by Zacks Equity Research

CONMED's (CNMD) adjusted fourth-quarter earnings misses while sales beat estimates on the back of strong growth in the United States and international markets. Gross margin improves with a rise in sales.

Philips' (PHG) New Innovation to Enhance Cardiovascular Imaging

by Zacks Equity Research

Philips' (PHG) latest X11-4t Mini 3D TEE transducer is likely to have an edge over the traditional 3D TEE in terms of catering to a broader range of patients and improved overall comfort.

LabCorp (LH) Unveils Test for Preeclampsia in Pregnant Women

by Zacks Equity Research

LabCorp (LH) test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia.

Why Universal Health Services (UHS) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Universal Health Services (UHS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation

by Zacks Equity Research

Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.

Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow

by Zacks Equity Research

Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.

Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View

by Zacks Equity Research

Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Thermo Fisher (TMO) Q4 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

Strength in PPI business contributed to Thermo Fisher's (TMO) fourth-quarter revenue growth.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) owing to its strength in the Breast Health and GYN Surgical segments.

Stryker's (SYK) Q4 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increased, with earnings and revenues beating estimates.

Cencora (COR) Beats on Q1 Earnings & Revenues, Ups 2024 Outlook

by Zacks Equity Research

Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Universal Health Services, Inc. (UHS) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG) on strong growth in Animal and Food Safety businesses.

Charles River (CRL) Launches Animal-Free Endotoxin Test

by Zacks Equity Research

Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.

ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries

by Zacks Equity Research

ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.

Here's Why Universal Health Services (UHS) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.